Breaking News, Collaborations & Alliances

Automolous Enters License Agreement with Center for Breakthrough Medicines

Agreement allows Autolomous to design, configure and integrate solutions for CBM utilizing the AutoloMATE platform.

Author Image

By: Charlie Sternberg

Associate Editor

Autolomous LTD, a developer of critical manufacturing management systems for Cell and Gene Therapies (CGT), has entered a license agreement with U.S.-based Center for Breakthrough Medicines (CBM), a cell and gene therapy contract development, manufacturing and testing organization (CDMO).   The agreement allows Autolomous to design, configure and integrate solutions for CBM utilizing the AutoloMATE platform, a business-critical robust digital system, providing CBM with seamless digital connect...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters